175 related articles for article (PubMed ID: 38175441)
1. Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy.
Wu JR; Shih PC; Li C; Chao HL; Wang HC; Chiang YM; Liu YJ; Hsu SC; Yao CY; Chen LH; Lin CC; Tien HF; Chou WC
J Hematop; 2023 Jun; 16(2):103-109. PubMed ID: 38175441
[TBL] [Abstract][Full Text] [Related]
2. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23);
Du J; Chisholm KM; Tsuchiya K; Leger K; Lee BM; Rutledge JC; Paschal CR; Summers C; Xu M
Pediatr Dev Pathol; 2021; 24(4):378-382. PubMed ID: 33749383
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy- (Blinatumomab-) Related Lineage Switch of
He RR; Nayer Z; Hogan M; Cuevo RS; Woodward K; Heyer D; Curtis CA; Peterson JF
Case Rep Hematol; 2019; 2019():7394619. PubMed ID: 31885955
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
5. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
Rayes A; McMasters RL; O'Brien MM
Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
[TBL] [Abstract][Full Text] [Related]
6. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
7. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A; Mikhailova E; Komkov A; Gaskova M; Abasov R; Matveev E; Kazanov M; Mamedov I; Shmitko A; Belova V; Miroshnichenkova A; Illarionova O; Olshanskaya Y; Tsaur G; Verzhbitskaya T; Ponomareva N; Bronin G; Kondratchik K; Fechina L; Diakonova Y; Vavilova L; Myakova N; Novichkova G; Maschan A; Maschan M; Zerkalenkova E; Popov A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409391
[TBL] [Abstract][Full Text] [Related]
8. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
[No Abstract] [Full Text] [Related]
9. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
Kantarjian H; Haddad FG; Jain N; Sasaki K; Short NJ; Loghavi S; Kanagal-Shamanna R; Jorgensen J; Khouri I; Kebriaei P; Alvarado Y; Kadia T; Paul S; Garcia-Manero G; Dabaja B; Yilmaz M; Jacob J; Garris R; O'Brien S; Ravandi F; Jabbour E
J Hematol Oncol; 2023 May; 16(1):44. PubMed ID: 37131217
[TBL] [Abstract][Full Text] [Related]
10. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
Ohana Z; Serraes S; Elder C; Katusa N
J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
[TBL] [Abstract][Full Text] [Related]
12. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
14. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
16. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).
Jia Y; Lin D; Wang Z; Li C; Wang H; Wang J; Mi Y
Diagn Pathol; 2022 Oct; 17(1):74. PubMed ID: 36199105
[TBL] [Abstract][Full Text] [Related]
19. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
20. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
